Isis Sees A “Fit” With Archemix In Developing Novel Oligonucleotide-Based Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms enter strategic alliance that provides Archemix access to four hundred Isis patents for developing proprietary aptamer therapeutics.